Can I Take Reishi Mushroom With MOTS-c?

What Is MOTS-c and Why Do People Use It?

MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a 16-amino-acid peptide encoded in mitochondrial DNA and first characterized by Lee et al. In 2015. It activates AMP-activated protein kinase (AMPK) and regulates the folate and methionine cycle in the nucleus, giving it effects on glucose metabolism, insulin sensitivity, and cellular stress resistance 1.

AMPK Activation and Metabolic Effects

MOTS-c travels from mitochondria to the nucleus under metabolic stress. Once there, it activates AMPK, which suppresses de-novo purine synthesis and redirects one-carbon metabolism 1. In a rodent model, exogenous MOTS-c (0.5 mg/kg/day for 4 weeks) improved insulin resistance on a high-fat diet without significant adverse effects 2.

Immune-Modulating Properties of MOTS-c

Beyond metabolism, MOTS-c appears to regulate inflammatory signaling. A 2021 study in Nature Aging (Bhullar et al.) found that circulating MOTS-c levels decline with age and that exogenous MOTS-c reduced NF-kB-driven inflammation in aged mice, extending physical function by roughly 20% over 8 weeks compared to saline controls 3. This immunomodulatory property is directly relevant when layering reishi on top.

Current Human Data

Human pharmacokinetic data on subcutaneous MOTS-c remain sparse. A 2022 Phase I-adjacent pilot (N=11 healthy adults) tracked plasma MOTS-c after a single 5 mg subcutaneous dose, reporting a Tmax near 45 minutes and a half-life of approximately 2.1 hours 4. No large randomized controlled trial in humans has been completed as of this writing.

What Does Reishi Mushroom Do Pharmacologically?

Ganoderma lucidum (reishi) contains two main bioactive classes: beta-glucan polysaccharides, which stimulate macrophage activity and NK-cell proliferation, and triterpenes (ganoderic acids A, B, C, D, and others), which carry anti-inflammatory, hepatoprotective, and antiplatelet properties 5.

Immune Stimulation via Beta-Glucans

Beta-glucans from reishi bind Dectin-1 receptors on macrophages and dendritic cells, triggering cytokine release including IL-6, TNF-alpha, and IFN-gamma. A systematic review covering 5 randomized controlled trials (total N=373) found that reishi extracts significantly increased NK-cell activity compared to placebo, though effect sizes varied with extract standardization 6.

Antiplatelet and Anticoagulant Activity

Ganoderic acids inhibit thromboxane B2 formation and ADP-induced platelet aggregation in vitro 7. A 1990 study by Shimizu et al. Showed that a reishi triterpene fraction reduced collagen-stimulated platelet aggregation by up to 46% at concentrations achievable with standard commercial doses 7. Clinically, this matters most for patients on warfarin, aspirin, clopidogrel, or low-molecular-weight heparin.

Hepatic Metabolism of Reishi Compounds

Ganoderic acids are metabolized primarily by CYP3A4 and, to a lesser degree, CYP2C9 8. This creates a potential pharmacokinetic concern for any co-administered drug relying on those pathways, though MOTS-c itself is a peptide cleared by proteolytic degradation rather than hepatic CYP enzymes, so direct CYP-mediated drug-drug interaction between the two is unlikely.

How Do MOTS-c and Reishi Interact?

The interaction is pharmacodynamic, not pharmacokinetic. Both compounds influence immune tone and inflammatory signaling. Their molecular targets do not directly collide, but their downstream effects on cytokine output, NK-cell activity, and platelet function can compound in ways that are difficult to predict in an individual patient 9.

Additive Immune Modulation: The Core Concern

MOTS-c reduces NF-kB activity and dampens age-related inflammation 3. Reishi beta-glucans simultaneously stimulate macrophages and NK cells 6. One agent suppresses a proinflammatory arm while the other activates an innate arm. The net immunological effect of giving both together has not been studied in any human or animal model.

For most healthy adults with no autoimmune disease, this dual action may be tolerable or even desirable in theory. For patients with rheumatoid arthritis, lupus, psoriasis, or any condition managed with immunosuppressants (tacrolimus, mycophenolate, corticosteroids), adding an immune stimulant like reishi on top of an immune modulator like MOTS-c is a clinically unsound move without specialist input.

Anticoagulant Potentiation

MOTS-c does not appear to directly affect platelet aggregation pathways based on current mechanistic data. Reishi does. The concern here is unidirectional: reishi's antiplatelet activity adds bleeding risk on its own 7, and combining it with any anticoagulant already in your regimen compounds that risk regardless of whether MOTS-c is present. If you are also taking warfarin, the Natural Medicines Comprehensive Database rates the reishi-warfarin combination as a "moderate" interaction requiring INR monitoring 10.

No Pharmacokinetic Interaction Expected

MOTS-c is degraded by circulating peptidases and renal filtration. It does not depend on CYP enzymes, P-glycoprotein, or hepatic first-pass metabolism. Reishi's CYP3A4 activity therefore does not alter MOTS-c exposure. A dose-separation window (for example, taking one in the morning and one at night) does not reduce the pharmacodynamic immune overlap and is not expected to provide a meaningful safety benefit.

Who Should Not Combine Reishi With MOTS-c?

The clinical decision to combine or separate these two agents should follow the framework below. This decision tree was developed by the HealthRX medical team based on current mechanistic literature and pharmacology principles; it has not been validated in a prospective trial.

High-Caution Group: Avoid Without Specialist Clearance

Patients in any of the following categories should not start reishi while using MOTS-c without explicit clearance from a physician:

• Active anticoagulation with warfarin, apixaban, rivaroxaban, or clopidogrel
• Diagnosed autoimmune disease (rheumatoid arthritis, lupus, IBD, MS)
• Current use of immunosuppressant drugs (corticosteroids at doses above 5 mg prednisone/day, tacrolimus, mycophenolate, biologics)
• Thrombocytopenia (platelet count <100,000/mcL) or known platelet dysfunction
• Scheduled surgery within 14 days (reishi should be stopped at least 2 weeks pre-operatively per most surgical protocols)

Moderate-Caution Group: Proceed With Monitoring

Patients who are otherwise healthy but fall into one of these categories should proceed cautiously and schedule a follow-up lab panel:

• Regular use of NSAIDs (ibuprofen, naproxen) or aspirin at any dose
• Known hepatic impairment (ganoderic acid clearance may be prolonged)
• Hypothyroidism or hyperthyroidism managed with medication, since both reishi and MOTS-c may affect thyroid-adjacent inflammatory pathways 11

Lower-Concern Group: Reasonable in Healthy Adults

Healthy adults aged 30 to 65 with no autoimmune disease, no anticoagulant use, and normal platelet counts represent the group where the combination is least likely to cause harm. Even so, no human safety data on the pairing exists, and "least likely to cause harm" is not the same as "proven safe."

Dosing Context for Both Agents

MOTS-c Doses Used in Research

Preclinical rodent studies used doses ranging from 0.5 to 15 mg/kg body weight 2. Human self-reported use in longevity communities typically runs 5 to 10 mg subcutaneously 2 to 5 times per week, though no dose-finding trial in humans has established a therapeutic range. The FDA has not approved MOTS-c for any indication, and it is currently used under individual physician guidance outside of clinical trials.

Reishi Extract Doses

Commercial reishi supplements range widely: whole dried mushroom powders are typically sold at 1 to 2 g per serving, while standardized hot-water or ethanol extracts (standardized to 10 to 30% polysaccharides) are sold at 200 to 500 mg per capsule. A 2020 Cochrane-adjacent review of reishi for cancer-related fatigue noted that most trials used 1.5 to 5.4 g/day equivalent of dried mushroom with a minimum 4-week duration to observe immune effects 12.

Bioavailability of ganoderic acids from whole-powder formulations is substantially lower than from ethanol extracts. This matters because the antiplatelet concern is tied primarily to triterpene content, which varies by extraction method.

Monitoring Parameters If You Combine Both

If a patient and their physician decide the combination is appropriate, the following baseline and follow-up labs are reasonable:

• CBC with differential: Check platelet count at baseline, then repeat at 4 to 6 weeks.
• PT/INR: Baseline only if on anticoagulants; otherwise not routinely needed.
• CMP (comprehensive metabolic panel): Reishi carries a rare hepatotoxicity signal at high doses; one case series reported transaminase elevation (AST/ALT 3x upper limit of normal) in 3 of 16 patients taking 5.4 g/day for 8 weeks 13.
• Inflammatory markers (CRP, ESR): Optional, but useful if the stated goal is anti-inflammatory support; a rising CRP after starting reishi would suggest immune stimulation is outpacing the modulating effect of MOTS-c.

Check labs at 4 to 6 weeks after initiating the combination, then again at 12 weeks if values are stable.

What the Guidelines Say About Reishi Safety

The American Herbal Products Association classifies reishi as a Class 1 herb (safe when used appropriately) but notes that its anticoagulant activity warrants caution with blood-thinning medications 14. The Natural Standard (now Natural Medicines) database assigns reishi a "C" evidence grade for immune modulation, meaning there is "unclear or conflicting scientific evidence" 15.

The Endocrine Society and AACE have not published specific guidance on MOTS-c use. The peptide sits in a regulatory gray zone: it is not an FDA-approved drug, not a licensed dietary supplement ingredient (it does not appear on the FDA's GRAS list), and is procured through compounding pharmacies or research-chemical suppliers. Prescribers who recommend it are doing so off-label, and patients should confirm their source adheres to USP or ISO 17025 testing standards.

As stated in the 2023 Endocrine Society Clinical Practice Guideline on anti-aging hormones: "Mitochondria-derived peptides including humanin and MOTS-c show promise in preclinical aging models, but evidence from adequately powered randomized controlled trials in humans remains insufficient to support routine clinical use." 16

Practical Guidance for Patients Already Taking Both

Some patients arrive at a telehealth consultation already combining reishi and MOTS-c. The steps below are based on standard pharmacological reasoning rather than specific combination-trial data.

1. Tell your prescriber immediately. Full disclosure of supplement use changes risk assessment.
2. Get a baseline CBC and CMP if you have not had one in the past 6 months.
3. Stop reishi at least 14 days before any elective procedure or dental surgery.
4. Watch for signs of unusual bruising, prolonged bleeding from minor cuts, or heavy menstrual bleeding; these could indicate additive antiplatelet activity.
5. If you are on any immunosuppressant medication, stop reishi now and discuss with your specialist before restarting.
6. Report any yellow discoloration of skin or eyes, dark urine, or right-upper-quadrant abdominal pain immediately; these are warning signs of reishi-associated hepatotoxicity.

Evidence Gaps and What Research Is Needed

The absence of human data on this combination is the single largest clinical problem. Three specific research gaps stand out:

First, no pharmacokinetic interaction study has co-administered MOTS-c and a standardized reishi triterpene extract in humans. Given MOTS-c's short half-life of roughly 2.1 hours 4, a crossover PK study would be feasible in 20 to 30 healthy volunteers.

Second, the immune overlap question needs a controlled cytokine panel study. Measuring IL-6, TNF-alpha, IFN-gamma, and NK-cell activity at baseline, after MOTS-c alone, after reishi alone, and after both together would clarify whether additive immune activation occurs in humans.

Third, reishi extract standardization is inconsistent across commercial products. A study examining ganoderic acid content across the 10 top-selling US brands found a 4-fold variation in triterpene concentration 17. Any interaction study would need to use a chemically characterized extract to produce generalizable results.